0000950170-24-004656.txt : 20240116
0000950170-24-004656.hdr.sgml : 20240116
20240116163545
ACCESSION NUMBER: 0000950170-24-004656
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240110
FILED AS OF DATE: 20240116
DATE AS OF CHANGE: 20240116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Neill Andrew R
CENTRAL INDEX KEY: 0001827204
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39593
FILM NUMBER: 24535619
MAIL ADDRESS:
STREET 1: 1018 W 11TH STREET, SUITE 100
CITY: AUSTIN
STATE: TX
ZIP: 78703
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Shattuck Labs, Inc.
CENTRAL INDEX KEY: 0001680367
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 812575858
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 500 W. 5TH STREET
CITY: AUSTIN
STATE: TX
ZIP: 78701
BUSINESS PHONE: 512-900-4690
MAIL ADDRESS:
STREET 1: 500 W. 5TH STREET
CITY: AUSTIN
STATE: TX
ZIP: 78701
4
1
ownership.xml
4
X0508
4
2024-01-10
0001680367
Shattuck Labs, Inc.
STTK
0001827204
Neill Andrew R
C/O SHATTUCK LABS, INC.
500 W. 5TH STREET, SUITE 1200
AUSTIN
TX
78701
false
true
false
false
Chief Financial Officer
true
Common Stock
2024-01-10
4
A
false
56500
0.00
A
200916
D
Common Stock
2024-01-10
4
F
false
2470
10.09
D
198446
D
Common Stock
2024-01-10
4
S
false
25000
10.00
D
173446
D
Stock Option (Right to Buy)
10.09
2024-01-10
4
A
false
113000
0.00
A
2034-01-10
Common Stock
113000
113000
D
Consists of 56,500 restricted stock units, which will vest in four equal annual installments beginning on January 10, 2025, subject to the Reporting Person's continued service to the Issuer.
This option represents a right to purchase a total of 113,000 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2025, with the remaining three quarters vesting in equal monthly installments through January 10, 2028, subject to the Reporting Person's continued service to the Issuer.
/s/ Andrew R. Neill
2024-01-16